Suppressing activity of the AKT/mTOR pathway with some of the factors effectively inhibits the tumor tissue activity (132, 133), but endometrial cancer therapies engaging only a single inhibiting factor are insufficiently effective as monotherapy (134); thus, using some factors enhancing the suppressing mTOR inhibitors effect significantly intensifies reducing endometrial cancer cell viability, colony formation ability, and induced apoptosis (135). This evidence concerns the gene AKT1 and endometrial cancer.